Operator of a biopharmaceutical company intended to offer investigational MDM2 inhibitor for cancer treatment.
Operator of a biopharmaceutical company intended to offer investigational MDM2 inhibitor for cancer treatment.
Drug Discovery📍 Redwood City, CAFounded 2018
Current Valuation
$700M
as of 2020-Q1
PRIVATE
QL Price
$700M
0% vs last round
QuantLogix's current estimate for Kartos Therapeutics, published 2026-09-27 — in line with the last disclosed round of $700M (2020-Q1).
Confidence
low
Basis
round anchored
What backs this price
Last disclosed round
$700M
2020-Q1
weight 0.01
How this price has held up
No round has priced for Kartos Therapeutics since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-27 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Kartos Therapeutics, 2026-09-27 (9a7ff1fd08ee59e3).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is Kartos Therapeutics going public?
No. Kartos Therapeutics is private and has not filed to go public. There is no S-1 on file.
What is Kartos Therapeutics' valuation in 2026?
Kartos Therapeutics is valued at $700M as of 2020-Q1, set by its Series B ($90M, Jan 2020). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Kartos Therapeutics filed an S-1?
No public S-1 is on file for Kartos Therapeutics.
How much has Kartos Therapeutics raised?
Kartos Therapeutics has raised $115M in total, most recently a Series B of $90M in Jan 2020.
Is Kartos Therapeutics publicly traded — can you buy Kartos Therapeutics stock?
No. Kartos Therapeutics is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Kartos Therapeutics on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Founded
2018
HQ
Redwood City, CA
Employees
87
Total Raised
$115M
Last Round
Series B — $90M (Jan 2020)
IPO Status
private
Fundraising Status
Series B · $90M · 6y 8mo ago
privateTotal raised $115M
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series B
$90M
Jan 2020
—
$700M
Vertical Intelligence — Biotech / Gene Therapy
Registered trials
16
4 active · 3 recruiting
Lead phase
Phase 3
most advanced registered study
Focus areas
Advanced Malignancy
Cancer · Oncology
Latest trial start
2024-06-03
Name-verified against lead sponsor "Kartos Therapeutics, Inc." on ClinicalTrials.gov as of 2026-09-19. Verify on ClinicalTrials.gov ↗
Talent Signal
No public careers page or job board could be found for Kartos Therapeutics as of 2026-09-16. That itself is a datapoint: no open external hiring surface.
Checked the company site and major hosted job boards. Re-checked monthly.
Biotechnology
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2020-Q1. Refreshed quarterly.